Jonathan is a partner in the Chemical and Life Sciences practice and leads Keltie's Cambridge office. He has extensive experience of working with clients in a wide range of technology areas including agri-tech, sustainability, pharmaceuticals, chemistry, therapeutic treatments, personal care devices, medical devices, medical diagnostics, healthcare, biotechnology, regenerative stem cell therapies, food packaging, gene-editing (CRISPR), CAR-T cell-based therapies, materials, catalysts, energy technologies and cosmetics.
Jonathan manages a number of global patent portfolios for start-ups and SME clients, and his burgeoning practice has a particular focus on start-up and spin-out companies.
Providing his clients with strategic, value-driven advice, Jonathan understands what clients need from their IP portfolio. He has been involved with numerous due diligence exercises for investment rounds, acquisition and licensing, and listings on the UK AIM stock exchange and the Nasdaq in the US.
Jonathan also has an extensive registered design practice and handles the portfolios of European and UK registered designs for a number of household-name international clients.
Prior to joining Keltie in 2011, Jonathan was a principal chemist at GlaxoSmithKline and has almost 10 years’ experience of working in the pharmaceutical sector in the epigenetic, immuno-inflammation, cardiovascular and respiratory disease areas.
Jonathan received a first-class honours degree in Natural Sciences from the University of Cambridge before gaining a PhD in organic chemistry with post-doctoral experience at the distinguished École Polytechnique, Paris, France.
23.02.2021Patenting ethical, environmental or socially responsible technologies
Can patent protection ever be part of an ethical or high moral value business model?
31.08.2021Re-registering EU designs in the UK: Three scenarios to double check before the 30 September re-filing deadline
The deadline for re-filing EU designs in the UK is looming on 30 September 2021. Make sure your UK rights are in place before this deadline, and in particular, double check these three scenarios where your UK design rights may not have been created automatically.
17.10.2022The Global Chip Shortage and Innovation
08.04.2022The EPO continues its pilot programme for video conference oral proceedings - an attorney perspective
OtherLess related knowledge